LUCIRA HEALTH INC (LHDX) Stock Price, Quote, News and Overview
NASDAQ:LHDX - Nasdaq - US54948U1051 - Common Stock - Currency: USD
LHDX Quote, Performance and Key Statistics
0.4523
-0.11 (-19.23%)
The current stock price of LHDX is 0.4523 USD. In the past month the price increased by 17.18%. In the past year, price decreased by -89.13%.
LHDX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 28.89 | 234.01B | ||
| ISRG | INTUITIVE SURGICAL INC | 80.74 | 211.07B | ||
| BSX | BOSTON SCIENTIFIC CORP | 41.63 | 154.00B | ||
| SYK | STRYKER CORP | 31.4 | 145.92B | ||
| MDT | MEDTRONIC PLC | 16.84 | 115.33B | ||
| BDX | BECTON DICKINSON AND CO | 16.35 | 65.30B | ||
| EW | EDWARDS LIFESCIENCES CORP | 27.98 | 43.23B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 20.29 | 41.62B | ||
| IDXX | IDEXX LABORATORIES INC | 40.25 | 37.07B | ||
| DXCM | DEXCOM INC | 53.81 | 34.68B | ||
| RMD | RESMED INC | 26.21 | 34.03B | ||
| PHG | KONINKLIJKE PHILIPS NVR- NY | 17.5 | 24.02B |
Related stock screener links
About LHDX
Company Profile
Lucira Health, Inc. provides DNA testing services for medical, forensics, chemical, industrial, and agricultural applications. The company is headquartered in Emeryville, California and currently employs 221 full-time employees. The company went IPO on 2021-02-05. The firm is focused on providing disposable, single use test kit platform to replace central lab testing for diagnosing infectious diseases which leads to treatment and disease control outcomes. The firm has developed a testing platform that produces high-complexity-laboratory-accurate molecular testing in a single-use and user-friendly test kit that is powered by two AA batteries and fits in the palm of a hand. The company is also engaged in the commercialization of commercializing its PCR-quality COVID-19 test kits. Through its polymerase chain reaction (PCR)-quality technology, the Company offers single-use testing for infectious diseases. Its test kits are coupled with its digital platform, LUCI PASS, which is designed to securely deliver a clinically relevant test result to users at home, healthcare providers, and to required public health authorities. The firm has its operations in United States and Canada, among others.
Company Info
LUCIRA HEALTH INC
1315 63Rd Street
Emeryville CALIFORNIA 94608 US
CEO: Erik T. Engelson
Employees: 221
Company Website: https://www.lucirahealth.com/
Phone: 18145741546.0
LUCIRA HEALTH INC / LHDX FAQ
What is the stock price of LUCIRA HEALTH INC today?
The current stock price of LHDX is 0.4523 USD. The price decreased by -19.23% in the last trading session.
What is the ticker symbol for LUCIRA HEALTH INC stock?
The exchange symbol of LUCIRA HEALTH INC is LHDX and it is listed on the Nasdaq exchange.
On which exchange is LHDX stock listed?
LHDX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for LUCIRA HEALTH INC stock?
6 analysts have analysed LHDX and the average price target is 0.77 USD. This implies a price increase of 69.14% is expected in the next year compared to the current price of 0.4523. Check the LUCIRA HEALTH INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is LUCIRA HEALTH INC worth?
LUCIRA HEALTH INC (LHDX) has a market capitalization of 18.36M USD. This makes LHDX a Nano Cap stock.
How many employees does LUCIRA HEALTH INC have?
LUCIRA HEALTH INC (LHDX) currently has 221 employees.
What are the support and resistance levels for LUCIRA HEALTH INC (LHDX) stock?
LUCIRA HEALTH INC (LHDX) has a resistance level at 0.88. Check the full technical report for a detailed analysis of LHDX support and resistance levels.
Is LUCIRA HEALTH INC (LHDX) expected to grow?
The Revenue of LUCIRA HEALTH INC (LHDX) is expected to grow by 201.55% in the next year. Check the estimates tab for more information on the LHDX EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy LUCIRA HEALTH INC (LHDX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of LHDX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of LHDX, evaluating the profitability, health, valuation and growth aspects
- LUCIRA HEALTH INC (LHDX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- LUCIRA HEALTH INC (LHDX) Sales and EPS estimates to see what analysts future expectations are.
- LUCIRA HEALTH INC (LHDX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- LUCIRA HEALTH INC (LHDX) Insider and Institutional Ownership to learn about the owners and their transactions.
- LUCIRA HEALTH INC (LHDX) Stock Chart to make your own analysis
- LUCIRA HEALTH INC (LHDX) Latest news and press-releases to stay up to date.
Does LUCIRA HEALTH INC (LHDX) stock pay dividends?
LHDX does not pay a dividend.
When does LUCIRA HEALTH INC (LHDX) report earnings?
LUCIRA HEALTH INC (LHDX) will report earnings on 2023-05-10.
What is the Price/Earnings (PE) ratio of LUCIRA HEALTH INC (LHDX)?
LUCIRA HEALTH INC (LHDX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.19).
LHDX Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to LHDX. When comparing the yearly performance of all stocks, LHDX is a bad performer in the overall market: 87.4% of all stocks are doing better.
LHDX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to LHDX. LHDX has a bad profitability rating. Also its financial health evaluation is rather negative.
LHDX Financial Highlights
Over the last trailing twelve months LHDX reported a non-GAAP Earnings per Share(EPS) of -3.19. The EPS decreased by -84.6% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0.48 |
LHDX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 43% to LHDX. The Buy consensus is the average rating of analysts ratings from 6 analysts.
For the next year, analysts expect an EPS growth of 83% and a revenue growth 201.55% for LHDX